Brii Biosciences inches closer to functional cure for hepatitis B but future is uncertain New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then. Written byAllison Whitten, PhD

Brii Biosciences inches closer to functional cure for hepatitis B but future is uncertain New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/brii-biosciences-inches-closer-to-functional-cure-for-hepatitis-b-but-future-is-uncertain-17480 The hepatitis B virus (HBV) vaccine is up to 90 percent effective at preventing HBV when given within 24 hours after birth. But for the hundreds of millions of people around the world who have already acquired the viral infection that attacks their liver, there is no cure. Current standard treatments consist of daily, lifelong antiviral therapies where the virus still hides within liver tissue.